BIAF - MCAP CO - bioAffinity Technologies

This price chart for bioAffinity Technologies (BIAF) confirms a market capitalization of 0.01. The business's defense relies on exclusive CyPath Lung patents and strict FDA oversight. The team consists of leading cytometrists and biologists utilizing scientific grants. Currently, bioAffinity Technologies is scaling the implementation of a non-invasive sputum analysis method, creating a high-precision tool for the preemptive detection of oncology.

Market capitalization represents the aggregate value of all shares, measuring the total market value of a business. The dynamics of this metric allow an investor to assess the degree of asset overvaluation and the risks of margin compression. The current market valuation of the issuer on the GURU.Markets platform visualizes the market reaction to inflationary pressure. For bioAffinity Technologies (BIAF), the growth of this metric reflects confidence in the scaling of the CyPath Lung diagnostic system, confirming the capitalization of successes within the R&D pipeline.